• Thumbnail for Natalizumab
    Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. It is a humanized monoclonal...
    43 KB (3,967 words) - 04:10, 13 June 2024
  • Thumbnail for Boxed warning
    antipsychotics, especially in elderly patients with dementia. As of 2006[update], natalizumab (marketed as Tysabri) received a boxed warning on its packaging due to...
    17 KB (1,853 words) - 17:59, 29 August 2024
  • Thumbnail for Progressive multifocal leukoencephalopathy
    various transplant drugs, which are meant to weaken the immune system. Natalizumab (Tysabri) was approved in 2004 by the FDA for the treatment of multiple...
    23 KB (2,414 words) - 19:20, 9 February 2024
  • beta 1a and natalizumab: Dangerous but effective. Linked with PML, but is remarkable that Natalizumab alone is also linked with it. Natalizumab and fingolimod...
    83 KB (9,405 words) - 11:49, 23 August 2024
  • Thumbnail for Crohn's disease
    et al. (International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2)...
    162 KB (18,417 words) - 20:04, 18 August 2024
  • Thumbnail for Multiple sclerosis
    confidence that natalizumab, cladribine, or alemtuzumab are decreasing relapses over a period of two years for people with RRMS. Natalizumab and interferon...
    170 KB (18,096 words) - 23:10, 2 September 2024
  • system disorders; and rare reports of cardiac failure.[citation needed] Natalizumab is an anti-integrin monoclonal antibody that has shown utility as induction...
    44 KB (4,614 words) - 00:50, 4 May 2024
  • Thumbnail for Antibody
    1146/annurev.immunol.19.1.163. PMID 11244034. Doggrell SA (June 2003). "Is natalizumab a breakthrough in the treatment of multiple sclerosis?". Expert Opinion...
    119 KB (13,400 words) - 17:29, 29 August 2024
  • Thumbnail for Biological therapy for inflammatory bowel disease
    treat IBD are integrin receptor antagonists such as vedolizumab and natalizumab and interleukin antagonists like ustekinumab. Prior to the development...
    28 KB (3,327 words) - 19:25, 25 July 2024
  • Thumbnail for Human polyomavirus 2
    reported in patients treated with the drug. The boxed warning for the drug natalizumab (Tysabri) includes a statement that Human polyomavirus 2 resulted in...
    22 KB (2,699 words) - 11:53, 27 August 2024
  • Thumbnail for Élan
    focused on physiological and neuropathic pain. Previously named Antegren, natalizumab is a drug co-marketed by Biogen Idec and Élan as "Tysabri". Tysabri is...
    7 KB (530 words) - 16:41, 3 January 2024
  • against the therapeutic antibody) infliximab -zumab humanized antibody natalizumab, bevacizumab -anib Angiogenesis inhibitors pazopanib, vandetanib -ciclib...
    26 KB (2,150 words) - 07:07, 12 June 2024
  • 2023 adalimumab-aaty/Yuflyma adalimumab/Humira August 2023 natalizumab-sztn/Tyruko natalizumab/Tysabri September 2023 tocilizumab-bavi/Tofidence tocilizumab/Actemra...
    95 KB (6,480 words) - 22:51, 13 May 2024
  • hepatitis. Muzolimine 1987 France, Germany, European Union Polyneuropathy. Natalizumab (Tysabri) 2005–2006 US Voluntarily withdrawn from US market because of...
    45 KB (1,903 words) - 01:44, 1 September 2024
  • L04AF08 Ritlecitinib L04AG01 Muromonab-CD3 L04AG02 Efalizumab L04AG03 Natalizumab L04AG04 Belimumab L04AG05 Vedolizumab L04AG06 Alemtuzumab L04AG07 Begelomab...
    3 KB (367 words) - 15:37, 25 January 2024
  • Thumbnail for Oligoclonal band
    developing progressive multifocal leukoencephalopathy during treatment with natalizumab". Annals of Neurology. 77 (3): 447–457. doi:10.1002/ana.24345. PMID 25581547...
    21 KB (2,556 words) - 18:03, 12 February 2024
  • FDA include: interferons beta-1a and beta-1b; monoclonal antibodies: natalizumab, alemtuzumab, ocrelizumab, ofatumumab, and ublituximab; and immunomodulators:...
    131 KB (14,018 words) - 08:00, 24 June 2024
  • Thumbnail for Interleukin 1 beta
    produce IL-1β. Treatment of multiple sclerosis with glatiramer acetate or natalizumab has also been shown to reduce the presence of IL-1β or its receptor....
    26 KB (3,273 words) - 13:58, 26 August 2024
  • Thumbnail for Biogen
    (dimethyl fumarate) Relapsing forms of multiple sclerosis 2013 2014 TYSABRI (natalizumab) Relapsing-remitting multiple sclerosis 2004 Re-introduced in 2006 2006...
    48 KB (3,872 words) - 07:23, 31 August 2024
  • Thumbnail for Fingolimod
    have been reported, which has also been reported in patients taking natalizumab (Tysabri), an approved multiple sclerosis drug. Fingolimod has also been...
    27 KB (2,539 words) - 05:53, 26 March 2024
  • Thumbnail for List of therapeutic monoclonal antibodies
    emtansine mab chimeric CD37 Narnatumab mab human MST1R (aka RON) cancer Natalizumab Tysabri mab humanized integrin α4 Y multiple sclerosis, Crohn's disease...
    136 KB (4,020 words) - 07:14, 15 August 2024
  • Lampalizumab† Letolizumab Ligelizumab† Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab...
    38 KB (4,316 words) - 10:24, 26 August 2024
  • Thumbnail for Interferon beta-1a
    Merck KGaA 4 $1.93 billion Fingolimod Gilenya Novartis 5 $1.41 billion Natalizumab Tysabri Biogen Idec 6 $1.38 billion Interferon beta 1b Betaseron/Betaferon...
    32 KB (2,851 words) - 23:22, 16 August 2024
  • Thumbnail for VLA-4
    an autoimmune reaction has been to block the action of VLA-4 (as with natalizumab) so that pathogenic T-cells are unable to enter the brain and thus unable...
    9 KB (1,032 words) - 14:42, 18 March 2024
  • Thumbnail for Marburg acute multiple sclerosis
    stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab". Journal of Neurology. 255 (9): 1436–1438. doi:10.1007/s00415-008-0956-x...
    9 KB (808 words) - 05:12, 13 December 2023
  • Thumbnail for Monoclonal antibody therapy
    GlaxoSmithKline 11/4/2015 subcutaneous humanized IL5 Severe asthma 125526 Link natalizumab Tysabri Biogen Idec 11/23/2004 intravenous humanized alpha-4 integrin...
    57 KB (4,072 words) - 11:12, 5 August 2024
  • Ruplizumab BLyS Belimumab CAT Bertilimumab Lerdelimumab Metelimumab Integrin Natalizumab Vedolizumab Interleukin-6 receptor Tocilizumab LFA-1 Odulimomab IL-2...
    7 KB (299 words) - 13:45, 27 April 2024
  • research leading to the first approved monoclonal antibody therapy for MS, Natalizumab (Tysabri), and clarified the molecular basis for how EBV triggers MS...
    16 KB (1,512 words) - 05:10, 3 September 2024
  • immunosuppressants used to treat MS—such as interferon-β, fingolimod, natalizumab, and alemtuzumab—worsen NMO disease progression and should not be used...
    68 KB (7,255 words) - 20:09, 14 August 2024
  • Nasarel nasaruplase (INN) nasaruplase beta (INN) Nascobal Nasonex Natacyn natalizumab (INN) natamycin (INN) nateglinide (INN) nateplase (INN) Natrecor Naturetin...
    7 KB (352 words) - 02:05, 1 July 2024